Molecular classification of breast carcinomas by immunohistochemical analysis: Are we ready?

Diagnostic Molecular Pathology

Volumn 18, Issue 3, 2009, Pages 125-132

  Tang, Ping ^a   Skinner, Kristin A ^a   Hicks, David G ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Breast carcinoma; CK5 6; EGFR; ER; HER2; Molecular classification; PR

Indexed keywords

BRCA1 PROTEIN; CYTOKERATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

BREAST CARCINOMA; CANCER CLASSIFICATION; CANCER RISK; CLASSIFICATION; GENE EXPRESSION PROFILING; HUMAN; IMMUNOHISTOCHEMISTRY; MICROARRAY ANALYSIS; MOLECULAR GENETICS; PRIORITY JOURNAL; RACE DIFFERENCE; REVIEW;

BREAST NEOPLASMS; CARCINOMA; HUMANS; IMMUNOHISTOCHEMISTRY; PATHOLOGY;

EID: 69749116768     PISSN: 10529551     EISSN: None     Source Type: Journal    
DOI: 10.1097/PDM.0b013e31818d107b     Document Type: Review

References (88)

1. Simpson PT, Reis-Filho JS, Gale T, et al. Molecular evolution of breast cancer. J Pathol. 2005;205:248-254.
2. Hyabittle JL, Blamey RW, Elston CW, et al. A prognostic index in primary breast cancers. Br J Cancer. 1982;45:361-366.
3. National Institutes of Health Consensus Development Panel. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst. 2001;93:979-989.
4. Bergh I, Holmquist M. Who should not receive adjuvant chemotherapy? International database. J Natl Cancer Inst Monogr. 2001;30:103-108.
5. Ravdin PM, Siminoff LA, Davis GJ, et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol. 2001;19:980-991. (Pubitemid 32176272)
6. Perou CM, Sorlie T, Eisen MB, et al. Molecular portrait of human breast tumours. Nature. 2000;406:747-752.
7. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869-10874. (Pubitemid 32878711)
8. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003;100:8418-8423. (Pubitemid 36842560)
9. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530-536.
10. van't Veer MJ, He YD, van de Vijver LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347:1999-2009.
11. Yu L, Lee CH, Tan PH, et al. Conservation of breast cancer molecular subtypes and transcriptional patterns of tumor progression across distinct ethnic populations. Clin Cancer Res. 2004;10:5508-5517.
12. van Laere SJ, van den Eynden GG, van der Auwera I, et al. Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profiling. Breast Cancer Res Treat. 2006;95:243-255.
13. Weight B, Hu Z, He X, et al. Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic progress of breast cancer. Cancer Res. 2005;65:9155-9158. (Pubitemid 41507977)
14. Boecker W, Moll R, Dervan P, et al. Usual ductal hyperplasia of the breast is a committed stem (progenitor) cell lesion distinct from atypical ductal hyperplasia and ductal carcinoma in situ. J Pathol. 2002;198:458-467. (Pubitemid 35446999)
15. Boecker W, Moll R, Poremba C, et al. Common adult stem cells in the human breast give rise to glandular and myoepithelial cell lineages: a new cell biological concept. Lab Invest. 2002;82:737-745. (Pubitemid 34633823)
16. Korsching E, Packeisen J, Agelopoulos K, et al. Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab Invest. 2002;82:1525-1533. (Pubitemid 35332911)
17. Fulford LG, Easton DF, Reis-Filho JS, et al. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology. 2006;49:22-34.
18. Tang P, Wang X, Schiffhauer L, et al. Relationship between nuclear grade of ductal carcinoma in situ and cell origin markers. Ann Clin Lab Sci. 2006;36:16-22. (Pubitemid 43805874)
19. Steinman S, Wang J, Bourne P, et al. Expression of cytokeratin markers, ER-alpha, PR, Her-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast. Ann Clin Lab Sci. 2007;37:127-134. (Pubitemid 46717189)
20. Laakso M, Loman N, Borg A, et al. Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors. Mod Pathol. 2005;18:1321-1328. (Pubitemid 41348650)
21. Jacquemier J, Padovani L, Rabayrol L, et al. Typical medullary breast carcinomas have a basal/myoepithelial phenotype. J Pathol. 2005;207:260-268. (Pubitemid 41556449)
22. Fulford LG, Reis-Filho JS, Ryder K, et al. Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Breast Cancer Res. 2007;9:R4. (Pubitemid 350215157)
23. Banerjee S, Reis-Filho JS, Ashley S, et al. Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J Clin Pathol. 2006;59:729-735. (Pubitemid 44048783)
24. Jones C, Ford E, Gillett C, et al. Molecular cytogenetic identification of subgroups of grade III invasive ductal carcinomas with different clinical outcomes. Clin Can Res. 2004;10:5988-5997. (Pubitemid 39287503)
25. van de Rijn M, Perou CM, Tibshirani R, et al. Expression of cytokeratin 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol. 2002;161:1991-1996. (Pubitemid 35434844)
26. Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triple negative breast cancer. Cancer. 2007;109:25-32. (Pubitemid 46120191)
27. Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype. A population-based study from the California Cancer Registry. Cancer. 2007;109:1721-1728.
28. Dent R, Trudeau M, Pritchard KI, et al. Triple negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429-4434. (Pubitemid 47219710)
29. Cleator S, Heller W, Coombes RC. Triple-negative breast cancer, therapeutic options. Lancet Oncol. 2007;8:235-244. (Pubitemid 46291713)
30. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13:2329-2334. (Pubitemid 46698581)
31. Tan DSP, Marchio C, Jones RL, et al. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline- treated patients. Breast Cancer Res Treat. 2007 [Epub ahead of print].
32. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10:5367-5374. (Pubitemid 39100473)
33. Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006;19:264-271. (Pubitemid 43117611)
34. Abd El-Rehim DM, Ball G, Finder SE, et al. High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer. 2005;116:340-350. (Pubitemid 40993329)
35. Tang P, Wang X, Schiffhauer L, et al. Expression patterns of ER-a, PR, HER2/neu, and EGFR in different cell origin subtypes of high grade and non-high grade ductal carcinoma in situ. Ann Clin Lab Sci. 2006;36:137-143.
36. Bryan BB, Schnitt SJ, Collins LC. Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer. Mod Pathol. 2006;19:617-621.
37. Dabbs DJ, Chivukula M, Carter G, et al. Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profiles. Mod Pathol. 2006;19:1506-1511. (Pubitemid 44624171)
38. Livasy CA, Perou CM, Karaca G, et al. Identification of a basal-like subtype of breast ductal carcinoma in situ. Human Pathol. 2007;38:197-204. (Pubitemid 46096566)
39. Lakhari SR, Reis-Filho JS, Fulford L, et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and breast phenotype. Clin Cancer Res. 2005;11:5175-5180. (Pubitemid 41003703)
40. Hicks DG, Short SM, Prescott NL, et al. Breast cancers with brain metastasis are more likely to be estrogen receptor negative, expression the basal cytokeratin CK5/6, and overexpression HER2 or EGFR. Am J Surg Pathol. 2006;30:1097-1104.
41. Siziopikou KP, Cobleigh M. The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies. Breast. 2007;16:104-107. (Pubitemid 46172864)
42. Matos I, Dufloth R, Alvarenga M, et al. p63, cytokeratin 5, and p-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch. 2005;477:688-694.
43. Tang P, Wang J, Bourne P. Molecular classifications of breast carcinoma with similar terminology and different definitions, are they the same? Human Pathol. 2008;39:506-513.
44. Abd El-Rehim DM, Pinder SE, Paish CE, et al. Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol. 2004;203:661-671. (Pubitemid 38714103)
45. Megha T, Ferrari F, Benvenuto A, et al. p53 mutant in breast cancer, correlation with cell kinetics and cell of origin. J Clin Pathol. 2003;55:461-466.
46. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina breast cancer study. J Am Med Assoc. 2006;295:2492-2502. (Pubitemid 43854964)
47. Early Breast Cancer Trialist' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet. 2005;365:1687-1717.
48. Colleoni M, Minchella I, Mazzarol G, et al. Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors. Ann Oncol. 2000;11:1057-1059. (Pubitemid 30739923)
49. Guarneri V, Broglio K, Kau SW, et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and others factors. J Clin Oncol. 2006;24:1037-1044. (Pubitemid 46638799)
50. Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to pre-operative chemotherapy. Clin Cancer Res. 2005;11:5678-5685. (Pubitemid 41170290)
51. Goldstein S, Decker D, Severson D, et al. Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete pathologic response after neoadjuvant chemotherapy. Cancer. 2007;110:1687-1696. (Pubitemid 47557293)
52. Badve S, Turbin D, Thorat MA, et al. FOXA1 expression in breast cancer - correlation with luminal subtype A and survival. Clin Cancer Res. 2007;13:4415-4421. (Pubitemid 47219708)
53. Rodriguez-Pinilla SM, Sarrio D, Honroado E, et al. Prognostic significance of basal-like phenotype and fasin expression in node negative invasive breast carcinomas. Clin Cancer Res. 2006;12:1533-1539.
54. Minn AJ, Gupta GP, Siegel PM, et al. Genes that mediate breast cancer metastasis to lung. Nature. 2005;436:518-524.
55. Charafe-Jauffret E, Ginestier C, Monville F, et al. Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene. 2006;25:2273-2284.
56. Ribeiro-Silva A, do Vale FR, Zucoloto S. Vascular endothelial growth factor expression in the basal subtype of breast carcinoma. Am J Clin Pathol. 2006;125:512-518.
57. Simon R, Panussis S, Maurer R, et al. KIT (CD117)-positive breast cancers are infrequent and lack KIT gene mutations. Clin Cancer Res. 2004;10:178-183. (Pubitemid 38114177)
58. Modi S, Seidman AD, Dickler R, et al. A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer. Breast Cancer Res Treat. 2005;90:157-163.
59. Troester MA, Hoadley KA, Sorlie T, et al. Cell-type-specific responses to chemotherapeutics in breast cancer. Cancer Res. 2004;64:4218-4226. (Pubitemid 38802426)
60. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302:634-646.
61. Chappuis PO, Nethercot V, Foulkes WD. Clinico-pathological characteristics of BRCA1- and BRCA2-related breast cancer. Semin Surg Oncol. 2000;18:287-295. (Pubitemid 30253021)
62. Foulkes WD, Stefansson IM, Chappuis PO, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst. 2003;95:1482-1485. (Pubitemid 37279334)
63. Olopade OI, Grushko T. Gene-expression profiles in hereditary breast cancer. N Engl J Med. 2001;344:2028-2029. (Pubitemid 32568161)
64. Rodriguez-Pinilla SM, Sarrio D, Honrado E, et al. Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas. J Clin Pathol. 2007;60:1006-1012. (Pubitemid 47441933)
65. Chlebowski RT, Chen Z, Anderson GL, et al. Ethnicity and breast cancer: factors influencing differences in incidences and outcome. J Natl Cancer Inst. 2005;97:439-448. (Pubitemid 40528607)
66. Gapstur SM, Dupuis J, Gann P, et al. Hormone receptor status of breast tumors in black, Hispanic, non-Hispanic white women. An analysis of 13,239 cases. Cancer. 1996;77:1465-1471.
67. Colditz GA, Rosner BA, Chen WY, et al. Risk factors for breast cancer according to estrogen and progesterone receptor status. J Natl Cancer Inst. 2004;96:218-228. (Pubitemid 38263181)
68. Chen WY, Hankinson SE, Schnitt SJ, et al. Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma. Cancer. 2004;101:1490-1500. (Pubitemid 39318893)
69. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: current status of the national surgical adjuvant breast and bowel project P-I study. J Natl Cancer Inst. 2005;97:1652-1662. (Pubitemid 41672231)
70. Suzuki R, Ye W, Rylander-Rudqvist T, et al. Alcohol and postmenopausal breast cancer risk defined by estrogen and progesterone receptor status: a prospective cohort study. J Natl Cancer Inst. 2005;97:1601-1608. (Pubitemid 41662714)
71. Marshall SF, Bernstein L, Anton-Culver H, et al. Nonsteroidal anti-inflammatory drug use and breast cancer risk by stage and hormonal receptor status. J Natl Cancer Inst. 2005;95:805-812. (Pubitemid 40909123)
72. Fung TT, Hu FB, McCullough ML, et al. Diet quality is associated with the risk of estrogen receptor-negative breast cancer in postmenopausal women. J Nutr. 2006;136:466-472. (Pubitemid 43228303)
73. Zhang SM, Hankinson SE, Hunter DJ, et al. Folate intake and risk of breast cancer characterized by hormone receptor status. Cancer Epidemiol Biomarkers Prev. 2005;14:2004-2008. (Pubitemid 41161215)
74. Millikan RC, Newman B, Tse CK, et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat. 2008;109:123-139.
75. Yang XR, Sherman ME, Rimm DL, et al. Differences in risk factors for breast cancer molecular subtypes in population-based study. Cancer Epidem Biomarkers Prev. 2007;16:439-443. (Pubitemid 46548646)
76. Jumppanen M, Gruvberger-Saal S, Kauraniemi P, et al. Basal-like phenotype is not associated with patient survival in estrogen receptor negative breast cancers. Breast Cancer Res. 2007;9:R16. (Pubitemid 350215145)
77. Sorlie T, Perou CM, Fan C, et al. Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer. Mol Cancer Ther. 2006;5:2914-2918. (Pubitemid 44849019)
78. Rennert G, Bisland-Naggan S, Barnett-Griness O, et al. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med. 2007;357:115-123. (Pubitemid 47057729)
79. NTR) in normal, benign and malignant breast tissue. Mod Pathol. 2006;19:307-319.
80. Laakso M, Tanner M, Nilsson J, et al. Basoluminal carcinoma: a new biologically and prognostically distinct entity between basal and luminal breast cancer. Clin Cancer Res. 2006;12:4185-4191.
81. Sidoni A, Cartaginese F, Colozza M, et al. ERCC1 expression in triple negative breast carcinoma: the paradox revisited. Breast Cancer Res Treat. 2007 [Epub ahead of print].
82. Kreike B, van Kouwenhove M, Horlings B, et al. Gene expression profiling and histopathological characterization of triple negative/basal-like carcinomas. Breast Cancer Res. 2007;9:R65. (Pubitemid 350187481)
83. Rakha EA, Putti TC, Abd El-Rehim DM, et al. Morphological and immunophenotypical analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol. 2006;208:495-506.
84. Peppercorn J, Perou CM, Carey LA. Molecular subtypes in breast cancer evaluation and management: divide and conquer. Cancer Invest. 2008;26:1-10.
85. Resi-Filho JS, Westbury C, Pierga JY. The impact of expression profiling on prognostic and predictive testing in breast cancer. J Clin Pathol. 2006;59:225-231. (Pubitemid 43344880)
86. Fan C, Oh DS, Wessels L, et al. Concordance among gene-expression-based predictors for breast cancer. N Engl JMed. 2006;355:560-569. (Pubitemid 44200649)
87. Simon R, Radmacher MD, Dobbin K, et al. Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J Natl Cancer Inst. 2003;95:14-18. (Pubitemid 36124291)
88. Reid JF, Lusa L, De Cecco L, et al. Limits of predictive models using microarray data for breast cancer clinical treatment outcome. J Natl Cancer Inst. 2005;97:927-930. (Pubitemid 41417944)